Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and further development for its drug candidates B001, B001-A, I022, and I022-K. B001, a monoclonal antibody (mAb) intended for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma (B-NHL), has been suspended following the completion of Phase I, incurring a development cost of RMB 64.67 million for Shanghai Pharmaceuticals.
The clinical program B001-A, which aimed to explore the use of B001 for multiple sclerosis (MS), had obtained clinical approval but had not yet progressed to clinical trials. I022, a Category 1 small molecule for the treatment of advanced breast cancer and liposarcoma, will no longer be pursued for first-line treatment in combination with letrozole. However, its development for other indications, including later-line treatment of breast cancer, breast cancer brain metastases in combination with endocrine therapy, and liposarcoma in combination with cadonilimab, will continue. The decision to halt the first-line treatment arm was made after the completion of Phase II, costing the company RMB 6.99 million in development funds.
Additionally, the Phase I clinical study for I022-K, a Category 1 small molecule targeting advanced solid tumors, has been terminated, with Shanghai Pharmaceuticals having invested RMB 40 million in its development.- Flcube.com
